NUMD:OTC.MKTS

Nu-Med Plus Inc.

The Nu-Med Plus mission is to design, develop and market new patented technologies in the medical field along with building key intellectual assets. The company's strategy is to focus on high-growth markets with a clearly defined need recognized by the medical community. Nu-Med's initial focus is on medical products that deliver therapeutic doses of Inhaled Nitric Oxide (INO) to patients. INO is used in neonatal hypertension and many pulmonary crises, in addition to having the potential to treat problems from malaria to wound healing. The company's product candidates are designed to be less expensive and more user-friendly for clinicians and end-users, as well as disruptive to the market.
NUMD:OTC.MKTS
This Utah-based company rolled out an online campaign that highlights its strategic repositioning.
read more >
Brett Earl
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system.
read more >
Ronald Day
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available.
read more >
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent.
read more >
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system.
read more >
This medical device company enters a partnership to provide quality and regulatory services.
read more >

Experts Following This Company

Ronald Day, Pediatric cardiologist

The information provided above is from analysts, newsletters, the company and other contributors.

Nu-Med Plus Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Nitric Oxide Delivery is an untapped emerging market with incredible potential
 
Nu-Med Plus is developing a high volume disruptive product, including its portable unit
 
Products will be low cost, user friendly and available to hospitals, clinics, ERT and 3rd work countries
catalyst Calendar